Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
divarasib + cetuximab + FOLFIRI
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
divarasib + cetuximab + FOLFIRI is a combination therapy under investigation for the treatment of cancers, specifically metastatic colorectal cancer. - **Divarasib** is a selective small molecule KRAS G12C inhibitor, designed to target and inhibit the activity of the KRAS G12C mutant oncoprotein. - **Cetuximab** is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), blocking EGFR-mediated signaling pathways involved in cell proliferation and survival. - **FOLFIRI** is a standard chemotherapy regimen containing folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. It works by disrupting DNA synthesis and cell division in rapidly dividing cancer cells[1][2][3]. This combination aims to block cancer growth through simultaneous inhibition of oncogenic KRAS-driven signaling, EGFR pathway inhibition, and cytotoxic effects of chemotherapy. The regimen is administered intravenously and primarily investigated in metastatic colorectal cancer, especially in patients with KRAS G12C mutations.
- Other names
- divarasib + cetuximab + FOLFIRI
02
Targets
TOP1 (DNA Topoisomerase I)EGFR T790M (Epidermal growth factor receptor T790M mutant)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)TS (Thymidylate synthase)
Beyond the preview
Go deeper on divarasib + cetuximab + FOLFIRI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on divarasib + cetuximab + FOLFIRI.